Sarepta Therapeutics to Host Webcast and Conference Call for the Duchenne Muscular Dystrophy Community on May 13, 2014

- Posted in CureDuchenne Blog, Research

April 28, 2014, 8:32 a.m. EDT

CAMBRIDGE, Mass., Apr 28, 2014 (BUSINESS WIRE) — Sarepta Therapeutics, Inc. /quotes/zigman/10874508/delayed/quotes/nls/srpt   SRPT  +1.17% , a developer of innovative  RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014,      beginning at 11:00 a.m. EDT (8:00 a.m. PDT / 5).
Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer  questions about Sarepta’s DMD development program, including upcoming clinical trials. Sarepta has invited DMD community representatives from leading patient advocacy groups to participate in the question and answer portion of the webcast.

To access the webcast, visit the events and presentations section of  Sarepta’s website at  www.sarepta.com/events  and follow the link for the webcast under “Upcoming Events.” Please    connect several minutes prior to the start of the broadcast to ensure  adequate time for any software download that may be necessary.

To access only the audio portion, dial in to 1-888-895-5479 (U.S. toll free) for U.S. domestic callers or 1-847-619-6250 for international callers. The passcode for the call is 37195657. Please specify to the  operator that you would like to join the “Sarepta DMD Development  Program Update.”

Following the event, the webcast will be archived in the events and  presentations section of Sarepta’s website for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based  therapeutics to improve and save the lives of people affected by serious  and life-threatening rare and infectious diseases. The company’s diverse  pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world’s most lethal infectious diseases. Sarepta aims to build a leading, independent  biotech company dedicated to translating its RNA-based science into  transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com .

SOURCE: Sarepta Therapeutics, Inc.

Sarepta Investor Contact:   Erin Cox, 857-242-3714   ecox@sarepta.com    or   Sarepta  Media Contact:  Jim Baker, 857-242-3710   jbaker@sarepta.com

Copyright Business Wire 2014

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.

Donate